A photo of Min Dong.

Min Dong, PhD

  • Member, Division of Translational and Clinical Pharmacology
  • Associate Professor, UC Department of Pediatrics



I am a researcher in the field of clinical pharmacology, and I came to Cincinnati Children’s in 2011. My areas of interest include pediatric pharmacokinetic/pharmacodynamic (PK-PD) modeling and simulation, individualized Bayesian dose optimization and clinical trial design.

My research goals are to use novel quantitative approaches to facilitate drug development and dose optimization for drugs such as antibiotics, immunosuppressants and cancer drugs in pediatric patients.

I have worked with my colleagues at Cincinnati Children’s, Drs. Patrick McGann and Russell Ware in the Division of Hematology and Dr. Alexander Vinks in the Division of Translational and Clinical Pharmacology, to develop a PK-guided Bayesian adaptive control algorithm to individualize the hydroxyurea dose in patients with sickle cell disease (SCD).

We recently reported the results of a prospective clinical trial (TREAT study: ClinicalTrials.gov NCT02286154) indicating that this PK-guided dosing approach is able to predict a safe starting dose of hydroxyurea. This can significantly reduce the time interval for patients to reach their personal maximum tolerated dose (MTD).

Our collaboration on sickle cell disease has also thrived with other research efforts. These include international studies performed in the Caribbean (EXTEND: NCT02556099) and in sub-Saharan Africa (REACH: NCT01966731 and NOHARM: NCT01976416), as well as studying hydroxyurea exposure in lactation (HELPS study).

BS: Peking University Medical Center, Beijing, China, 2000.

PhD: University of Cincinnati, Cincinnati, OH, 2010.

Postdoctoral Fellowship: T32 Cincinnati Pediatric Clinical Pharmacology Postdoctoral Training Program, Cincinnati, OH, 2016.


Pediatric pharmacokinetic/pharmacodynamics (PK-PD) modeling and simulation; individualized Bayesian dose optimization; clinical trial design

Research Areas

Clinical Pharmacology



Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: Current evidence and knowledge gaps. Dong, M; Ware, RE; Dallmann, A; Vinks, AA. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023; 43:419-429.


Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. Dong, M; Emoto, C; Fukuda, T; Arnold, DE; Mehta, PA; Marsh, RA; Vinks, AA. British Journal of Clinical Pharmacology. 2022; 88:248-259.


Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis. Dong, M; Rodriguez, AV; Blankenship, CA; McPhail, G; Vinks, AA; Hunter, LL. Journal of Antimicrobial Chemotherapy. 2021; 76:2923-2931.


Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine. Dong, M; McGann, PT. Clinical Pharmacology and Therapeutics. 2021; 109:73-81.


Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.


Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. Dong, M; McGann, PT; Mizuno, T; Ware, RE; Vinks, AA. British Journal of Clinical Pharmacology. 2018; 84:1410-1412.


Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents. Dong, M; Fukuda, T; Selim, S; Smith, MA; Rabinovich-Guilatt, L; Cassella, JV; Vinks, AA. Clinical Pharmacokinetics. 2017; 56:1207-1217.


Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Dong, M; McGann, PT; Mizuno, T; Ware, RE; Vinks, AA. British Journal of Clinical Pharmacology. 2016; 81:742-752.


Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. Ngamprasertwong, P; Dong, M; Niu, J; Venkatasubramanian, R; Vinks, AA; Sadhasivam, S. PloS one. 2016; 11:e0146563.


Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Dong, M; Fukuda, T; Cox, S; de Vries, MT; Hooper, DK; Goebel, J; Vinks, AA. British Journal of Clinical Pharmacology. 2014; 78:1102-1112.